Evaluate The Efficacy of Panchkarma Protocol in The Management of Kampavata (Parkinson’s Disease) An Open Labelled Randomized Controlled Clinical Trial

This clinical trial is designed to evaluate the efficacy of a Panchakarma protocol—comprising Virechana, Karma Basti, and Shirobasti followed by Brihmana Snehapana with Masha Taila—in the management of Kampavata (Parkinson’s Disease). The study is an open-label, randomized, controlled, double-arm interventional trial to be conducted at the Department of Panchakarma, National Institute of Ayurveda, Jaipur. A total of 70 patients aged 30–70 years with clinical features of Kampavata, including bradykinesia, tremors, rigidity, postural changes, and gait disturbances, will be enrolled. Patients will be randomly allocated into two groups: Group A receiving Panchakarma protocol with Masha Taila-based interventions, and Group B receiving standard control (Levodopa-Carbidopa therapy). The intervention will be carried out over 75 days with a 30-day follow-up. Primary outcome measures include changes in serum dopamine levels, while secondary outcomes include improvements in Unified Parkinson’s Disease Rating Scale (UPDRS), symptom severity (Kampa, Stambha, Chestasanga, Vakvikriti, Avanamana, Gatisanga), and quality of life (PDQ-8). Statistical analysis will be performed using both parametric and non-parametric methods, with significance set at p<0.05. The trial aims to establish whether Panchakarma therapy provides superior clinical benefits compared to standard therapy in Parkinson’s disease.